The beneficial effect of curcumin on the course of MAFLD was also confirmed in the meta-analysis of 16 randomized clinical trials conducted by Lukkunaprasit et al. It was shown that the use of curcumin by patients with MAFLD was associated with a decrease in the concentration of AST [MD = (−3.90); 95% CI: (−5.97)–(−1.82)], a decrease in ALT [MD = (−5.61); 95% CI: (−9.37)–(−1.85)], an increase in the resolution of hepatic steatosis (as measured using ultrasonography) (MD = 3.53; 95% CI: 2.01–6.22), and a reduced fasting blood sugar, body-mass index, and total cholesterol concentration [218]. The gene discussed is GPT; the disease is Hepatic steatosis.